|  |  |  |  |
| --- | --- | --- | --- |
| **Gene** | **Full Name** | **Forward primer** | **Reverse Primer** |
| *Il1b* | Interleukin 1β | TCAGGAAGGCAGTGTCACTCA | TCCACGGGCAAGACATAGGT |
| *Ilra* | Interleukin receptor antagonist | AAGAAAAGATAGACATGGTGCCTATTG | GCTTGCCCCCGTGGAT |
| *Il1r1* | Interleukin 1β receptor 1 | CGGAAATTGAATGGGACGAT | TGAAGGGTGTTCCAAAAACTGA |
| *Il6* | Interleukin 6 | ACTATGAGGTCTACTCGGCAAACC | ACAGTGAGGAATGTCCACAAACTG |
| *Il6r* | Interleukin 6 receptor | CCTGCGAGGTGGAGATCCT | ACTGTTTGCAACGCACAGTGA |
| *Gp130* | Glycoprotein 130, interleukin 6 signal transducer | TTATATCTACCCTGAGTTTCCAGTTGTC | TTTAGCACACAAGTGGCAGTGA |
| *Tnfa* | Tumor necrosis factor α | CACGGGAGCCGTGACTGTA | TCCAAGCGAACTTTATTTCTCTCA |
| *Tnfr1* | Tumor necrosis factor α receptor 1 | TGGAGGACCGTACCCTGATTT | GAGCCCCGGGTTAGAAAGG |
| *Tnfr2* | Tumor necrosis factor α receptor 2 | GGGTTATGCACTGTGAGTTGGA | CTGCGTGGGCCCTTCA |
| *Nfκb* | Nuclear factor kappa B subunit p65 | CATGGCAGACGACGATCCTT | TGGAGTGAGTCAAAGCAGTATTCAA |
| *Nfkbia* | NFκB inhibitor α (IκB) | CGGAGGACGGAGACTCGTT | CCATGGTCAGTGTCTTCTCTTCAT |
| *Cox2* | Cyclooxygenase 2 | AAATATGATGTTCGCATTCTTTGC | CCTCGCTTCTGATCTGTCTTGA |
| *Itgam* | Integrin alpha M (Cd11b) | TGACGGCTCCGGTAGCAT | CCATCACAGTTGAGACAAATTCCT |
| *Tgfb1* | Transforming growth factor β 1 | CACCCGCGTGCTAATGGT | TGTGATGTCTTTGGTTTTGTCATAGA |
| *Tgfb2* | Transforming growth factor β 2 | CGGTGGCGCTCAGTCTGT | GCGCATAAACTGGTCCATGTC |
| *Tgfbr1* | Transforming growth factor β receptor 1 | TGGCGGAATCCACGAAGA | CGGATGGATCAGAAGGTACAAGA |
| *Tgfbr2* | Transforming growth factor β receptor 2 | TGACAACCAGAAGTCTTGCATGA | GCGGCTTCTCACAGATGGA |
| *Crh* | Corticotropin releasing hormone | CCTTCTGAGGGAAGTCTTGGAAAT | TGCTGTGAGCTTGCTGAGCTA |
| *Nr3c2* | Nuclear receptor subfamily 3, group C, member 2 (MR) | CTTTACGAAGTGTTTCTACTGGATCCT | TGACACCCAGAAGCCTCATCT |
| *Nr3c1* | Nuclear receptor subfamily 3, group C, member 1 (GR) | GGGACCACCTCCCAAGCT | ACCCCGTAATGACATCCTGAAG |
| *Hsd11b1* | 11-β hydroxysteroid dehydrogenase 1 | TGGAAGACATGGCTTTTGCA | TCCAGTCCACCCAAGAGCTT |
| *Hsd11b2* | 11-β hydroxysteroid dehydrogenase 2 | TGCAACCTTTGAGAGGATGCTA | GGCCCCACATGTCTAATCATTC |
| *Bdnf* | Brain-derived neurotrophic factor | CATAAGGACGCGGACTTGTACA | AGCAGAGGAGGCTCCAAAGG |
| *Ntrk2* | Neurotrophic tyrosine kinase, receptor, type 2 (TrkB) | ACAAACCCAAATTACCCTGAAGTC | GTTTGTAGTATCCCCGATGTCAGTT |
| *Ngf* | Nerve growth factor | CATAGCGTAATGTCCATGTTGTTCT | TCTGCCTGTACGCCGATCA |
| *Ntrk1* | Neurotrophic tyrosine kinase, receptor, type 1 (TrkA) | TGTGGGAGGTCGGACCAT | TGAACTTGCGGTAGAGGATGCT |
| *Syp* | Synaptophysin | CCCACCTCCTTCTCCAATCA | CACCCGTGGGATCTTCATG |
| *Syt* | Synaptotagmin | AGGAGGAGCTGAGGGAAGTCA | GACAATGGAGAGCTATAATTTTCTGTTTAA |
| *Nrgn* | Neurogranin | GGGTTGTGGCTGGAAGGTTT | TTCACATTCCAACCCAGTATGG |
| *Gap43* | Growth associated protein 43 (neuromodulin) | GGAAAGTGCCCGACAGGAT | CTTAAAGTTCAGGCATGTTCTTGGT |
| *Dlgap2* | Discs large homolog-associated protein 2 | ACGCTCCAATTCCTAGTTTGCT | GGAGCCCGATGTCCTTCA |

Supplemental Table S1. Sequences of primers used for qPCR.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Plasma Cytokine** | **C+Saline**n=8 | **C+LPS**n=8 | **HF/HFr+Saline**n=8 | **HF/HFr+LPS**n=8 |
| **IL-6** | 0.00 ± 0.00 a | 1888.26 ± 767.90 b | 27.56 ± 7.94 c | 519.58 ± 324.48 d |
| **TNFα** | 24.14 ± 16.43 a | 81.98 ± 33.39 c | 0.00 ± 0.00 b | 35.71 ± 19.63 a, c |
| **IL-10** | 0.00 ± 0.00 a | 529.91 ± 118.76 b | 0.00 ± 0.00 a | 307.42 ± 80.52 b |
| **Hypothalamic expression** | **C+Saline**n=8 | **C+LPS**n=8 | **HF/HFr+Saline**n=8 | **HF/HFr+LPS**n=8 |
| **IL-6** | 1.05 ± 0.125 a | 369.95 ± 4.37 b | 0.65 ± 0.08 a | 443.94 ± 3.00 c |
| **TNFα** | 1.08 ± 0.16 a | 21.54 ± 1.50 b | 1.25 ± 0.25 a | 28.85 ± 0.82 c |
| **Hippocampal expression** | **C+Saline**n=8 | **C+LPS**n=8 | **HF/HFr+Saline**n=8 | **HF/HFr+LPS**n=8 |
| **IL-6** | 1.07 ± 0.14 a | 212.55 ± 8.84 b | 1.98 ± 0.24 a | 248.99 ± 9.64 c |
| **TNFα** | 1.10 ± 0.17 a | 48.74 ± 2.22 b | 2.14 ± 0.36 a | 71.34 ± 0.76 c |

Supplemental Table S2. Plasma cytokines (pg/ml) and central expression of cytokines (Fold changes) according to the diet, control (C) or HF/HFr, in response to saline or LPS in Experiment 1. The relative expression level of the target gene (Fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. For the same cytokine, data with different letters differ significantly (*P*<0.05).

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Body composition** | **C** n=20 | **C****+Str** n=10 | **CN**n=20 | **CN****+Str** n=10 | **HF/HFr**n=20 | **HF/HFr****+Str** n=10 | **HF/HFr****+CN** n=20 | **HF/HFr****+CN+Str** n=10 |
| **Body weight** | 409.4 ± 6.9 | 403.6 ± 11.2 | 417.6 ± 6.8 | 424.9 ± 13.9 | 399.5 ± 6.5 | 400.2 ± 8.7 | 422.1 ± 7.2 | 405.4 ± 15.0 |
| **Inguinal fat** | 1.03 ± 0.04 | 1.17 ± 0.10 | 1.00 ± 0.07 | 1.01 ± 0.10 | 1.09 ± 0.07 | 1.07 ± 0.10 | 1.13 ± 0.08 | 1.02 ± 0.10 |
| **Mesenteric fat** | 2.26 ± 0.10 | 2.28 ± 0.16 | 2.02 ± 0.08 | 1.93 ± 0.09 | 2.09 ± 0.08 | 2.07 ± 0.08 | 2.12 ± 0.09 | 2.15 ± 0.23 |
| **Liver** | 2.23 ± 0.02 | 2.19 ± 0.04 | 2.30 ± 0.05 | 2.38 ± 0.07 | 3.10 ± 0.08ddd | 2.91 ± 0.13ddd | 3.02 ± 0.08ddd | 2.73 ± 0.08ddd s |

Supplemental Table S3. Final body weight, inguinal and mesenteric fats and liver weight (g/100g body weight) according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cytokine** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **IL-6** | 1.10 ± 0.10 n=20 | 0.39 ± 0.08sss n=10 | 1.04 ± 0.12 n=17 | 1.23 ± 0.18nnn n=9 | 1.04 ± 0.11 n=18 | 1.52 ± 0.14ddd s n=9 | 0.87 ± 0.09 n=18 | 0.98 ± 0.17n n=9 |
| **IL-6R** | 1.04 ± 0.06 n=20 | 1.10 ± 0.08 n=8 | 0.94 ± 0.06 n=19 | 0.88 ± 0.06n n=10 | 1.27 ± 0.09d n=20 | 1.12 ± 0.13 n=10 | 0.84 ± 0.02nnn n=18 | 0.90 ± 0.08 n=9 |
| **Gp130** | 1.03 ± 0.06 n=20 | 0.89 ± 0.03 n=10 | 1.10 ± 0.09 n=20 | 1.28 ± 0.31 n=10 | 1.15 ± 0.10 n=19 | 1.16 ± 0.11d n=10 | 1.04 ± 0.06 n=20 | 0.86 ± 0.12n n=10 |
| **TNFα** | 1.24 ± 0.18 n=19 | 0.44 ± 0.11sss n=10 | 0.63 ± 0.08nnn n=20 | 0.54 ± 0.11 n=10 | 0.68 ± 0.11ddd n=19 | 0.43 ± 0.13s n=10 | 1.05 ± 0.15d n=19 | 0.42 ± 0.11ss n=10 |
| **TNFR1** | 1.05 ± 0.07 n=20 | 1.03 ± 0.11 n=10 | 0.93 ± 0.08 n=20 | 0.97 ± 0.08 n=9 | 0.88 ± 0.06 n=19 | 0.98 ± 0.11 n=10 | 0.98 ± 0.08n=19 | 0.96 ± 0.13 n=9 |
| **TNFR2** | 1.08 ± 0.10 n=20 | 1.30 ± 0.14 n=10 | 1.22 ± 0.10 n=20 | 1.26 ± 0.12 n=9 | 1.10 ± 0.10 n=19 | 1.26 ± 0.15 n=10 | 0.96 ± 0.06 n=19 | 1.22 ± 0.18 n=9 |

Supplemental Table S4. Hypothalamic expression of pro-inflammatory cytokines and receptors according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cytokine** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **IL-6** | 1.13 ± 0.14 n=20 | 0.67 ± 0.10sss n=10 | 1.15 ± 0.13 n=20 | 1.32 ± 0.16nnn n=10 | 1.19 ± 0.13 n=20 | 1.70 ± 0.20ddd s n=10 | 1.07 ± 0.15 n=20 | 1.35 ± 0.17 n=10 |
| **IL-6R** | 1.07 ± 0.09 n=20 | 1.78 ± 0.14ss n=10 | 1.08 ± 0.15 n=19 | 2.16 ± 0.20sssn=10 | 1.53 ± 0.06dd n=20 | 1.33 ± 0.06d n=9 | 1.11 ± 0.07nnn n=19 | 1.35 ± 0.07dd s n=10 |
| **Gp130** | 1.05 ± 0.08 n=20 | 0.70 ± 0.06s n=10 | 0.92 ± 0.07 n=20 | 0.95 ± 0.09 n=10 | 0.91 ± 0.07 n=20 | 1.00 ± 0.08d n=10 | 0.89 ± 0.07 n=20 | 1.07 ± 0.15 n=10 |
| **TNFα** | 1.34 ± 0.17 n=20 | 0.43 ± 0.09sss n=10 | 1.88 ± 0.24 n=20 | 1.24 ± 0.26nn n=10 | 1.85 ± 0.22d n=20 | 1.16 ± 0.26d s n=10 | 1.64 ± 0.17 n=20 | 0.88 ± 0.25ss n=10 |
| **TNFR1** | 1.04 ± 0.07 n=20 | 0.70 ± 0.05sss n=10 | 1.10 ± 0.07 n=20 | 1.32 ± 0.08nnn s n=10 | 1.07 ± 0.07 n=20 | 1.74 ±0.19ddd sss n=10 | 0.99 ± 0.06 n=20 | 1.09 ± 0.09nnn n=10 |
| **TNFR2** | 1.23 ± 0.27 n=20 | 0.92 ± 0.23 n=10 | 0.72 ± 0.05n n=20 | 0.71 ± 0.06 n=10 | 0.72 ± 0.07d n=20 | 0.74 ± 0.09 n=10 | 0.78 ± 0.11 n=20 | 0.55 ± 0.45s n=10 |

Supplemental Table S5. Hippocampal expression of pro-inflammatory cytokines and receptors according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Actors of inflammation** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **NFκB** | 1.05 ± 0.07n=20 | 0.78 ± 0.07ssn=10 | 0.75 ± 0.04nnnn=20 | 0.93 ± 0.10sn=10 | 0.78 ± 0.05ddn=19 | 0.78 ± 0.07 n=10 | 0.82 ± 0.04 n=20 | 0.76 ± 0.06 n=10 |
| **IκB** | 4.04 ± 0.08n=20 | 2.07 ± 0.30sss n=9 | 1.13 ± 0.17nn n=19 | 2.41 ± 0.17sss n=10 | 1.18 ± 0.10ddd n=20 | 2.05 ± 0.11sss n=10 | 1.24 ± 0.17 n=19 | 1.93 ± 0.18sss n=10 |
| **COX2** | 1.13 ± 0.15 n=20 | 1.50 ± 0.30 n=10 | 0.71 ± 0.08nn n=20 | 1.19 ± 0.16ss n=10 | 0.79 ± 0.11d n=19 | 0.87 ± 0.12dd n=10 | 0.78 ± 0.07 n=20 | 0.78 ± 0.09dd n=10 |
| **ITGAM** | 1.15 ± 0.18 n=20 | 0.92 ± 0.09 n=10 | 0.98 ± 0.05 n=19 | 0.98 ± 0.16 n=10 | 0.95 ± 0.06 n=19 | 0.89 ± 0.08 n=10 | 1.08 ± 0.10 n=20 | 0.92 ± 0.08 n=10 |
| **TGFβ1** | 1.09 ± 0.11 n=20 | 0.75 ± 0.06s n=10 | 0.70 ± 0.03nnn n=20 | 0.91 ± 0.13 n=9 | 0.80 ± 0.08d n=19 | 0.88 ± 0.07 n=10 | 0.95 ± 0.12 n=19 | 0.95 ± 0.18 n=9 |
| **TGFβ2** | 1.04 ± 0.07 n=20 | 1.06 ± 0.11 n=10 | 0.93 ± 0.05 n=20 | 1.07 ± 0.10 n=9 | 1.06 ± 0.07 n=19 | 1.00 ± 0.09 n=10 | 1.03 ± 0.12 n=20 | 0.91 ± 0.09 n=10 |
| **TGFβR1** | 1.08 ± 0.09 n=18 | 0.62 ± 0.06sss n=10 | 0.55 ± 0.05nnn n=20 | 0.60 ± 0.03 n=10 | 0.72 ± 0.04dd n=18 | 1.18 ± 0.12dd ss n=10 | 0.72 ± 0.08 n=19 | 0.79 ± 0.11nn n=10 |
| **TGFβR2** | 1.05 ± 0.07n=18 | 0.67 ± 0.07ss n=10 | 0.64 ± 0.06nnn n=20 | 0.67 ± 0.05 n=10 | 0.73 ± 0.06dd n=18 | 1.06 ± 0.10dd s n=9 | 0.75 ± 0.07 n=18 | 0.86 ± 0.13 n=10 |

Supplemental Table S6. Hypothalamic expression of intermediates of transduction and targets of pro-inflammatory cytokines, and of anti-inflammatory cytokines according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Actors of inflammation** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **NFκB** | 1.04 ± 0.08 n=20 | 0.86 ± 0.04s n=10 | 1.02 ± 0.07 n=20 | 1.05 ± 0.07 n=10 | 1.03 ± 0.06 n=20 | 1.03 ± 0.11 n=10 | 1.01 ± 0.06 n=20 | 1.09 ± 0.09 n=10 |
| **IκB** | 1.11 ± 0.13 n=20 | 1.49 ± 0.12s n=10 | 0.86 ± 0.11n n=20 | 1.33 ± 0.14ss n=10 | 0.77 ± 0.08d n=20 | 1.50 ± 0.15sss n=10 | 0.86 ± 0.15 n=20 | 1.40 ± 0.14ss n=10 |
| **COX2** | 1.16 ± 0.14 n=20 | 0.83 ± 0.09 n=10 | 1.08 ± 0.08 n=20 | 0.90 ± 0.07 n=10 | 1.00 ± 0.05 n=20 | 0.98 ± 0.06 n=10 | 1.08 ± 0.15 n=20 | 0.89 ± 0.09 n=10 |
| **ITGAM** | 1.12 ± 0.13 n=18 | 0.89 ± 0.10 n=9 | 0.88 ± 0.10 n=20 | 1.03 ± 0.15 n=10 | 0.98 ± 0.07 n=16 | 1.15 ± 0.15 n=8 | 0.89 ± 0.07 n=16 | 1.08 ± 0.12 n=8 |
| **TGFβ1** | 1.09 ± 0.12 n=18 | 1.18 ± 0.16 n=9 | 1.03 ± 0.08 n=16 | 1.22 ± 0.11 n=8 | 1.08 ± 0.07 n=17 | 1.06 ± 0.09 n=9 | 1.35 ± 0.19 n=18 | 1.06 ± 0.09 n=9 |
| **TGFβ2** | 1.28 ± 0.17 n=20 | 1.05 ± 0.23 n=10 | 1.26 ± 0.21 n=20 | 1.37 ± 0.27 n=10 | 1.43 ± 0.18 n=20 | 1.26 ± 0.20 n=10 | 1.63 ± 0.23 n=20 | 1.14 ± 0.22 n=10 |
| **TGFβR1** | 1.07 ± 0.09 n=18 | 0.76 ± 0.06s n=10 | 0.93 ± 0.08 n=20 | 0.98 ± 0.09 n=10 | 0.91 ± 0.06 n=20 | 0.80 ± 0.08 n=10 | 0.83 ± 0.08 n=20 | 0.86 ± 0.11 n=10 |
| **TGFβR2** | 1.13 ± 0.13 n=20 | 0.87 ± 0.09s n=10 | 1.00 ± 0.12 n=20 | 1.08 ± 0.16 n=10 | 1.02 ± 0.10 n=20 | 0.99 ± 0.13 n=10 | 1.13 ±0.14 n=20 | 0.94 ± 0.15 n=10 |

Supplemental Table S7. Hippocampal expression of intermediates of transduction and targets of pro-inflammatory cytokines, and of anti-inflammatory cytokines according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.





Supplemental Figure S8. Hypothalamic (A.) and hippocampal (B.) expression of 11β-HSD1 and 2 according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Actors of plasticity** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **SYT** | 1.02 ± 0.04 n=20 | 0.98 ± 0.03 n=9 | 0.89 ± 0.02 n=20 | 1.15 ± 0.04s n=9 | 1.02 ± 0.02 n=19 | 1.05 ± 0.04 n=10 | 1.24 ± 0.06dd n n=19 | 0.89 ± 0.02d sssn=9 |
| **NRGN** | 1.07 ± 0.09 n=20 | 1.40 ± 0.15s n=9 | 1.14 ± 0.06 n=19 | 1.41 ± 0.11sn=9 | 1.32 ± 0.11 n=18 | 1.26 ± 0.11 n=10 | 1.34 ± 0.06 n=17 | 1.27 ± 0.17 n=8 |
| **GAP43** | 1.05 ± 0.07 n=20 | 0.97 ± 0.10 n=10 | 0.89 ± 0.05 n=20 | 0.98 ± 0.10 n=10 | 1.01 ± 0.05 n=19 | 1.01 ± 0.11 n=10 | 1.07 ± 0.06 n=20 | 1.01 ± 0.09 n=10 |

Supplemental Table S9. Hypothalamic expression of SYT, NRGN and GAP43 according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Actors of plasticity** | **C** | **C****+Str** | **CN** | **CN****+Str** | **HF/HFr** | **HF/HFr****+Str** | **HF/HFr****+CN** | **HF/HFr****+CN+Str** |
| **SYT** | 1.04 ± 0.07 n=20 | 1.02 ± 0.07 n=10 | 1.02 ± 0.05 n=20 | 1.16 ± 0.07 n=10 | 1.13 ± 0.05 n=20 | 1.07 ± 0.06 n=10 | 1.02 ± 0.06 n=20 | 1.09 ± 0.08 n=10 |
| **NRGN** | 1.06 ± 0.06 n=20 | 0.93 ± 0.07 n=10 | 1.07 ± 0.04 n=20 | 1.16 ± 0.10 n=10 | 1.10 ± 0.06 n=19 | 1.08 ± 0.11 n=10 | 1.12 ± 0.09 n=20 | 1.08 ± 0.08 n=10 |
| **GAP43** | 1.05 ± 0.08 n=20 | 0.91 ± 0.03s n=10 | 1.00 ± 0.06n n=20 | 1.02 ± 0.10 n=10 | 1.00 ± 0.06d n=19 | 0.96 ± 0.08 n=10 | 0.98 ± 0.05 n=20 | 1.02 ± 0.07 n=10 |

Supplemental Table S10. Hippocampal expression of SYT, NRGN and GAP43 according to the diet (C vs. HF/HFr), the cinnamon (CN) supplementation or the stress (Str) condition. The relative expression level of the target gene (fold-change) was expressed as 2 – ΔΔCT, when compared to the mean ΔCT of the control group. d: diet effect, n: cinnamon effect, s: stress effect, with reference to their control. x: *P*<0.05, xx: *P*<0.01, xxx: *P*<0.001.